|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
|
Feasibility of predicting AML response to induction chemotherapy
|
1R43CA221473-01
|
$299,999
|
$299,999
|
HENDERSON, PAUL
|
ACCELERATED MEDICAL DIAGNOSTICS, LLC
|
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S1
|
$50,000
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S2
|
$149,785
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
|
The Madrina Network Web Portal
|
3R44CA177037-03S1
|
$34,313
|
|
MATIELLA, ANA
|
ACMA SOCIAL MARKETING
|
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
|
Fluorescent Nanodiamonds for Multiplexed Imaging and Diagnostics
|
1R43CA232901-01
|
$291,083
|
|
SHENDEROVA, OLGA
|
ADAMAS NANOTECHNOLOGIES, INC.
|
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
3R43CA217502-01A1S1
|
$2,000
|
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
4R44CA224460-02
|
$1,111,364
|
|
DAUNCH, WILLIAM
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
|
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
|
1R43CA232977-01
|
$298,444
|
|
MARLEAU, ANNETTE
|
AETHLON MEDICAL, INC.
|
|
|
Training African Pathologists in Cancer Diagnosis
|
1R13CA232439-01
|
$38,120
|
|
WILSON, MICHAEL
|
AFRICAN STRATEGIES /ADVANCING PATHOLOGY
|
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Womens Interagency HIV Study (WIHS-V)
|
3U01AI035004-25S1
|
$144,370
|
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Genetic and Dietary Interactions in MMR Deficient Colon Tumorigenesis
|
1R01CA222358-01A1
|
$635,306
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
5R01CA182284-05
|
$346,525
|
$346,525
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-04
|
$346,525
|
$173,263
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
$364,614
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
$437,537
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
PI3K Isoform Dependence in Adult Hematopoiesis and Myeloid Leukemia
|
5R01CA196973-02
|
$409,153
|
$409,153
|
GRITSMAN, KIRA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Epigenetic activity of normal and cancer-associated mutant H1 linker histones
|
5F30CA210539-02
|
$44,044
|
$22,022
|
HEALTON, SEAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Synergistic co-targeting of pro-apoptotic BAX and anti-apoptotic BCL-XL in cancer
|
1F31CA236434-01
|
$44,524
|
|
LOPEZ-ARROYO, ANDREA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Mechanisms of Formation and Progression of Preleukemic Stem Cells
|
1R01CA217092-01
|
$397,371
|
$397,371
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Role of a Novel Homeobox Transcription Factor (HLX) in Acute Myeloid Leukemia
|
5R01CA166429-06
|
$384,342
|
$384,342
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Assay Development for NSD1 Methyltransferase Inhibitor Discovery
|
5R01CA191077-03
|
$312,244
|
$312,244
|
KOLB, EDWARD
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
|
Novel IL-15 Superagonist Therapy for Bladder Cancer
|
6R44CA156740-05
|
$999,919
|
|
RHODE, PETER
|
ALTOR BIOSCIENCE. LLC
|
|
|
Highly Multiplexed Nanoscale Mass Spectrometric Imaging of Cancer Tissues
|
1R43CA236097-01
|
$300,000
|
|
LIM, MARK
|
AMBERGEN, INC
|
|
|
11th AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
|
1R13CA236113-01
|
$74,000
|
|
FOTI, MARGARET
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
|
Integrative Molecular Epidemiology Workshop
|
2R25CA174664-06
|
$258,400
|
|
SELLERS, THOMAS
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
|
Colon cancer risk-stratification via optical analysis of rectal ultrastructure
|
3R44CA199667-02S1
|
$2,000
|
|
WALI, RAMESH
|
AMERICAN BIOOPTICS, LLC
|
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
3R01CA201179-03S1
|
$227,376
|
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors
|
3R01CA182901-04S1
|
$39,254
|
|
LARKEY, LINDA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Therapeutic peptide for hepatocellular carcinoma
|
1R43CA232947-01
|
$299,983
|
|
PANDEY, NIRANJAN
|
ASCLEPIX THERAPEUTICS, LLC
|
|
|
AML-MutationCounter, a tool to detect residual and recurrent leukemia
|
1R41CA213690-01
|
$220,087
|
$220,087
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
|
Create three-member project team to refine commercialization plans for AML-Mutation Counter, a tool to detect residual and recurrent leukemia.
|
3R41CA213690-01S1
|
|
$0
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
|
Genetic Analysis of Myeloproliferative Disease
|
3R01CA076167-14S1
|
$24,361
|
$24,361
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
|
|
Genetic Analysis of Myeloproliferative Disease
|
5R01CA076167-14
|
$307,800
|
$307,800
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
|
|
Novel Biomarkers for the Clinical Management of Bladder Cancer
|
1R01CA227277-01A1
|
$466,211
|
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
5R01CA132640-16
|
$270,000
|
$270,000
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
|
P53-dependent immunogenic DCs in the tumor microenvironment
|
1R50CA232983-01
|
$203,853
|
|
SHARMA, MADHAV
|
AUGUSTA UNIVERSITY
|
|
|
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer
|
1R44CA232963-01
|
$299,937
|
|
GLODE, MIKE
|
AURORA ONCOLOGY, INC.
|
|
|
Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy
|
1R44CA233143-01
|
$218,588
|
|
LAMPI HERMANSON, DAVID
|
B-MOGEN BIOTECHNOLOGIES, INC.
|
|
|
Integrative Oncology: From Research to Practical Applications
|
1R13CA236121-01
|
$5,000
|
|
RAO, SANTOSH
|
BANNER HEALTH
|
|
|
Improving pathologic nodal staging of resected lung cancer
|
2R01CA172253-06
|
$499,347
|
|
OSAROGIAGBON, RAYMOND
|
BAPTIST MEMORIAL HOSPITAL - TIPTON
|
|
|
Proteogenomic Translational Research Center for Clinical Proteomic
|
1U01CA214116-01
|
$1,374,609
|
$1,374,609
|
RODLAND, KARIN
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
|
Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies
|
3U19CA203654-02S1
|
$147,830
|
|
AMOS, CHRISTOPHER
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Cancer-associated fibroblast in the regulation of bladder cancer stem cells
|
3R01CA175397-05S1
|
$110,950
|
|
CHAN, KEITH SYSON
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis
|
1R01CA230848-01
|
$442,560
|
|
FU, LONING
|
BAYLOR COLLEGE OF MEDICINE
|
|
Total relevant funding to Leukemia for this search: $291,343,273
|
